DS
BCRX icon

DRW Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

DRW Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
31,234
+9,389
+43% +$84.9K 0.01% 592
2026
Q1 		$208K Buy
21,845
+9,448
+76% +$73.4K ﹤0.01% 1094
2025
Q4 		$96.7K Sell
12,397
-92,919
-88% -$672K ﹤0.01% 1071
2025
Q3 		$788K Buy
105,316
+94,637
+886% +$788K 0.01% 445
2025
Q2 		$95.7K Buy
+10,679
New +$99.5K ﹤0.01% 1022
2024
Q3 		– Sell
-11,987
Closed -$74.1K – 565
2024
Q2 		$74.1K Buy
+11,987
New +$66.1K ﹤0.01% 496

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DRW Securities's BCRX Position: Q2 2026 in Review

DRW Securities increased its BioCryst Pharmaceuticals (BCRX) stake by 43% in Q2 2026, buying an estimated $84.9K and bringing the position to 31,234 shares worth $312K. The position accounts for 0.01% of the portfolio, ranked #592.

DRW Securities first reported a position in BCRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $788K in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • DRW Securities held 31,234 shares of BioCryst Pharmaceuticals worth $312K as of Q2 2026.
  • DRW Securities bought 9,389 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $84.9K.
  • BioCryst Pharmaceuticals made up 0.01% of DRW Securities's portfolio in Q2 2026, its #592 holding.
  • DRW Securities first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • DRW Securities's BioCryst Pharmaceuticals position peaked at $788K in Q3 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.